A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys

BACKGROUND: The treatments currently approved for Duchenne muscular dystrophy (DMD), a progressive skeletal muscle wasting disease, address the needs of only a small proportion of patients resulting in an urgent need for therapies that benefit all patients regardless of the underlying mutation. Myos...

Descripción completa

Detalles Bibliográficos
Autores principales: St. Andre, Michael, Johnson, Mark, Bansal, Prashant N., Wellen, Jeremy, Robertson, Andrew, Opsahl, Alan, Burch, Peter M., Bialek, Peter, Morris, Carl, Owens, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679155/
https://www.ncbi.nlm.nih.gov/pubmed/29121992
http://dx.doi.org/10.1186/s13395-017-0141-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679155/
https://www.ncbi.nlm.nih.gov/pubmed/29121992
http://dx.doi.org/10.1186/s13395-017-0141-y

Ejemplares similares